Literature DB >> 22453573

Optimal duration of adjuvant therapy for patients with resected gastrointestinal stromal tumors.

Charles D Blanke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22453573     DOI： 10.1001/jama.2012.368

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  2 in total

1.  Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.

Authors:  Martin H Cohen; John R Johnson; Robert Justice; Richard Pazdur
Journal:  Oncologist       Date:  2012-05-29

2.  Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach.

Authors:  Anthony Paul Conley; Annie Guérin; Medha Sasane; Geneviève Gauthier; Frances Schwiep; Christopher Hunt Keir; Eric Q Wu
Journal:  J Gastrointest Cancer       Date:  2013-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.